RNA-based drugs and vaccines

References

• Drews J. Drug discovery: a historical perspective. Science 2000;291:1960-4
   Google Scholar
• Dimitrov DS. Therapeutic proteins. Methods Mol Biol 2012;899:1-26
   PubMedGoogle Scholar
• Salzman A. Adrenoleukodystrophy patient perspective: turning despair into a gene therapy breakthrough. Hum Gene Ther 2011;22:647-8
   PubMedGoogle Scholar
• Lundstrom K. Present and future approaches to screening of G protein-coupled receptors. Fut Med Chem 2013;5:523-38
   PubMed Web of Science ®Google Scholar
• Chen J, Xie J. Progress on RNAi-based molecular medicines. Int J Nanomedicine 2012;7:3971-80
   PubMed Web of Science ®Google Scholar
• Hannon GJ. RNA interference. Nature 2002;418:244-51
   PubMed Web of Science ®Google Scholar
• Pushparaj PN, Aarthi JJ, Manikandan J, et al. siRNA, miRNA and shRNA: in vivo applications. J Dent Res 2008;87:992-1003
   PubMedGoogle Scholar
• Lund E, Sheets MD, Imboden SB, et al. Limiting Ago protein restricts RNAi and microRNA biogenesis during early development in Xenopus laevis. Genes Dev 2011;25:1121-31
   PubMedGoogle Scholar
• Bhattacharayya SN, Habermacher R, Martine U, et al. Relief of microRNA-mediated translational repression in human cells subjected to stress. Cell 2006;125:1111-24
   PubMedGoogle Scholar
• Lundstrom K. Alphavirus-based vaccines. Viruses 2014;6:2392-415
   PubMed Web of Science ®Google Scholar
• Van Lint S, Heirman C, Thielemans K, et al. mRNA: from a chemical blueprint for protein production to an off-the-shelf therapeutic. Hum Vaccin Immunother 2013;9:265-74
   PubMed Web of Science ®Google Scholar
• Tsai WH, Chang WT. Construction of simple and efficient siRNA validation systems for screening and identification of effective RNAi-targeted sequences from mammalian genes. Methods Mol Biol 2014;1101:321-38
   PubMedGoogle Scholar
• Reynolds A, Leake D, Boese Q, et al. Rational siRNA design for RNA interference. Nat Biotechnol 2004;22:326-30
   PubMed Web of Science ®Google Scholar
• Shirane D, Sugao K, Namiki S, et al. Enzymatic production of RNAi libraries from cDNAs. Nat Genet 2004;36:190-6
   PubMed Web of Science ®Google Scholar
• Shukla S, Sumaria CS, Pradeepkumar PI. Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook. Chem Med Chem 2010;5:328-49
   Web of Science ®Google Scholar
• Krutzfeldt J, Rajewsky N, Braich R, et al. Silencing of microRNAs in vivo with “antagomirs”. Nature 2005;438:685-9
   PubMed Web of Science ®Google Scholar
• Williford JM, Wu J, Ren Y, et al. Recent advances in nanoparticle-mediated siRNA delivery. Annu Rev Biomed Eng 2014;16:347-70
   PubMed Web of Science ®Google Scholar
• Van den Boorn JG, Schlee M. Coch C, et al. siRNa delivery with exosome nanoparticles. Nat Biotechnol 2011;29:325-6
   PubMed Web of Science ®Google Scholar
• Sutton D, Kim S, Shuai X, et al. Efficient suppression of secretory clusterin levels by polymer-siRNA nanocomplexes enhances ionizing radiation lethality in human MCF-7 breast cancer cells in vitro. Int J Nanomedicine 2006;1:155-62
   PubMed Web of Science ®Google Scholar
• Wu Y, Wang W, Chen Y, et al. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 2010;5:129-36
   PubMed Web of Science ®Google Scholar
• Choi KY, Silvestre OF, Huang X, et al. A versatile RNA-interference nanoplatform for systemic delivery of RNAs. ACS Nano 2014;8(5):4559-70
   PubMed Web of Science ®Google Scholar
• Wang HX, Yang XZ, Sun CY, et al. Matrix metalloproteinase 2-responsive micelle for siRNA delivery. Biomaterials 2014;35(26):7622-34
   PubMed Web of Science ®Google Scholar
• Lares MR, Rossi JJ, Ouellet DL, et al. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010;28:570-9
   PubMed Web of Science ®Google Scholar
• Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007;448:39-43
   PubMed Web of Science ®Google Scholar
• Lafon M. Rabies virus receptors. J Neurovirol 2005;11:82-7
   PubMed Web of Science ®Google Scholar
• Pulford B, Reim N, Bell A, et al. Liposome-siRNA-peptide complexes cross the blood-brain barrier and significantly decrease PrP on neuronal cells and PrP in infected cell cultures. PLoS One 2010;5:e11085
   PubMed Web of Science ®Google Scholar
• Morissey DV, Lockridge JA, Shaw L, et al. Potent and present in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005;23:1002-7
   PubMedGoogle Scholar
• Tekmirapharm.com. Tekmirapharma Pharmaceuticals Completes ApoB SNALP Phase I Clinical Trial. British Columbia. Available from: http://files.shareholder.com/downloads
   Google Scholar
• Geisbert TW, Lee ACH, Robbins ML, et al. Postexposure protection of non-human primates against a lethal dose of Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet 2010;375:1896-905
   PubMed Web of Science ®Google Scholar
• Rippel RA, Seifalian AM. Gold revolution – gold nanoparticles for modern medicine and surgery. J Nanosci Nanotechnol 2011;11:3740-8
   PubMedGoogle Scholar
• Guo S, Huang Y, Jiang Q, et al. Enhanced gene delivery and siRNA silencing by gold nanoparticles coated with charge-reversal polyelectrolyte. ACS Nano 2010;4:5505-11
   PubMed Web of Science ®Google Scholar
• Kong W, Bae K, Jo S, et al. Cationic lipid-coated gold nanoparticles as efficient and non-cytotoxic intracellular siRNA delivery vehicles. Pharm Res 2012;29:363-74
   Google Scholar
• Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004;431:371-8
   PubMed Web of Science ®Google Scholar
• Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005;11:423-8
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Eigenbrod S, Al-Khadra S, et al. Lentivector-mediated RNAi efficiently suppresses prion protein and prolongs survival of scrapie-infected mice. J Clin Invest 2006;116:3204-10
   PubMed Web of Science ®Google Scholar
• Shimizu S, Hong P, Arumugam B, et al. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010;115:1534-44
   PubMed Web of Science ®Google Scholar
• Benitec.com. Update on phase 1b clinical trial. Available from: www.benitec.com
   Google Scholar
• Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett 2005;5:1797-808
   PubMed Web of Science ®Google Scholar
• Davis ME, Zuckerman JE, Choi CHJ, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70
   PubMed Web of Science ®Google Scholar
• Kim SS, Peer D, Kumar P, et al. RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 2010;18:370-6
   PubMed Web of Science ®Google Scholar
• Rodriguez-Gascon A, del Pozo-Rodriguez A, Solinis MA. Development of nucleic acid vaccines of self-amplifying RNA in lipid nanoparticles. Int J Nanomedicine 2014;9:1833-43
   PubMed Web of Science ®Google Scholar
• Schott JW, Galla M, Godinho T, et al. Viral and non-viral approaches for transient delivery of mRNA and proteins. Curr Gene Ther 2011;11:382-98
   PubMed Web of Science ®Google Scholar
• Lentacker I, Vandenbroucke RE, Lucas B, et al. New strategies for nucleic acid delivery to conquer cellular and nuclear membranes. J Control Release 2008;132:279-88
   PubMed Web of Science ®Google Scholar
• Kofler RM, Aberle JH, Aberle SW, et al. Mimicking live flavivirus immunization with a noninfectious RNA vaccine. Proc Natl Acad Sci USA 2004;101:1951-6
   PubMed Web of Science ®Google Scholar
• Yu H, Babiuk LA, van Drunen-Little van den Hurk S. Immunity and protection by adoptive transfer of dendritic cells transfected with hepatitis C NS3/4A mRNA. Vaccine 2007;25:1701-10
   PubMed Web of Science ®Google Scholar
• Alcaraz-Estrada SL, Reichert ED, Padmanabhan R. Construction of self-replicating subgenomic West Nile virus replicons for screening antiviral compounds. Methods Mol Biol 2013;1030:283-99
   PubMedGoogle Scholar
• Reynard O, Mokhonov V, Mokhonova E, et al. Kunjin virus replicon-based vaccines expressing Ebola virus glycoprotein GP protect the guinea pig against lethal Ebola virus infection. J Infect Dis 2011;204(Suppl 3):S1060-5
   PubMedGoogle Scholar
• Hoang-Le D, Smeenk L, Anraku I, et al. A Kunjin replicon vector encoding granulocyte macrophage colony-stimulating factor for intra-tumoral gene therapy. Gene Ther 2009;16:190-9
   PubMed Web of Science ®Google Scholar
• Anraku I, Mokhonov VV, Rattanasena P, et al. Kunjin replicon-based simian immunodeficiency virus gag vaccines. Vaccine 2008;26:3268-76
   PubMed Web of Science ®Google Scholar
• Liljeström P, Garoff H. A new generation of animal cell expression vectors based on the Semliki Forest virus replicon. Biotechnology 1991;9:1356-61
   PubMed Web of Science ®Google Scholar
• Xiong C, Levis R, Shen P, et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 1989;243:1188-91
   PubMed Web of Science ®Google Scholar
• Davis NL, Brown KW, Johnston RE. In vitro synthesis of infectious Venezuelan equine encephalitis virus RNA from a cDNA clone: analysis of a viable deletion mutant. Virology 1989;171:189-204
   PubMed Web of Science ®Google Scholar
• Ying H, Zaks TZ, Wang RF, et al. Cancer therapy using a self-replicating RNA vaccine. Nat Med 1999;5:823-7
   PubMed Web of Science ®Google Scholar
• Geall AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 2012;109:14604-9
   PubMed Web of Science ®Google Scholar
• Pickard MR, Williams GT. Regulation of apoptosis by long non-coding RNA GAS5 in breast cancer cells: implications for chemotherapy. Breast Cancer Res Treat 2014;145(2):359-70
   PubMed Web of Science ®Google Scholar
• Pijlman GP, Suhrbier A, Khromykh AA. Kunjin virus replicons: an RNA-based, non-cytopathic viral vector system for protein production, vaccine and gene therapy applications. Expert Opin Biol Ther 2006;6:135-45
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Alphaviruses in gene therapy. Viruses 2009;1:13-25
   PubMedGoogle Scholar
• Murphy AM, Morris-Downes MM, Sheahan BJ, et al. Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Ther 2000;7:1477-82
   PubMed Web of Science ®Google Scholar
• Smyth JW, Fleeton MN, Sheahan BJ, et al. Treatment of rapidly growing K-BALB and CT26 mouse tumors using Semliki Forest virus recombinant particles. Gene Ther 2005;12:147-59
   PubMedGoogle Scholar
• Vähä-Koskela MJ, Kallio JP, Jansson LC. Oncolytic capacity of attenuated replicative Semliki Forest virus in human melanoma xenografts in severe combined immunodeficient mice. Cancer Res 2006;66:7185-94
   PubMed Web of Science ®Google Scholar
• Ren H, Boulikas T, Lundstrom K, et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication incompetent Semliki Forest virus vector carrying the human interleukin-12 gene – a phase I/II protocol. J Neurooncol 2003;64:147-54
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Biology and application of alphaviruses in gene therapy. Gene Ther 2005;12(Suppl 1):S92-7
   PubMed Web of Science ®Google Scholar
• Garba AO, Shaker AM. Bevasiranib for the treatment of wet, age-related macular degeneration. Ophtalmol Eye Dis 2010;2:75-83
   PubMedGoogle Scholar
• TheFreeLibrary.com. Update on phase III clinical trial on bevasiranib. Available from: www.freelibrary.com
   Google Scholar
• Tekmirapharm.com. Update on phase I clinical trial on TKM-PLK1. Available from: http://investor.tekmirapharm.com
   Google Scholar
• Tekmirapharm.com. Update on phase I clinical trial on TKM-Ebola. Available from: http://investor.tekmirapharm.com
   Google Scholar
• Quark. Available from: www.quarkpharma.com/QBI-EN/products/qpi1007/
   Google Scholar
• Kita Y, Vincent K, Natsugoe S, et al. Epigenetically regulated microRNAs and their prospect in cancer diagnosis. Expert Rev Mol Diagn 2014;14:673-83
   PubMed Web of Science ®Google Scholar
• Cipollini M, Landi S, Gemignani F. MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Pers Med 2014;7:173-91
   PubMedGoogle Scholar
• Gao Y, Zhao H, Lu Y, et al. MicroRNAs as potential diagnostic biomarkers in renal cell carcinoma. Tumour Biol 2014. [Epub ahead of print]
   Google Scholar
• Rocci A, Hofmeister CC, Pichiorri F. The potential of miRNAs as biomarkers for multiple myeloma. Expert Rev Mol Diagn 2014. [ Epub ahead of print]
   PubMedGoogle Scholar
• Wang M, Huang Y, Liang Z, et al. Plasma miRNAs might be promising biomarkers of chronic obstructive pulmonary disease. Clin Respir J 2014;doi: 10.1111/crj.12194. [ Epub ahead of print]
   Google Scholar
• Zhang W, Zhang C, Chen H, et al. Evaluation of microRNAs miR-196a, miR-30a-5P, and miR-490 as biomarkers of disease activity among patients with FSGS. Clin J Am Soc Nephrol 2014; pii: CJN.11561113. [ Epub ahead of print]
   Google Scholar
• Løvendorf MB, Zibert JR, Gyldenløve M, et al. MicroRNA-223 and miR-143 are important systemic biomarkers for disease activity in psoriasis. J Dermatol Sci 2014;75:133-9
   PubMed Web of Science ®Google Scholar
• Abu-Halima M, Hammadeh M, Backes C, et al. A panel of five microRNAs as potential biomarkers for the diagnosis and assessment of male infertility. Fertil Steril 2014; pii: S0015-0282(14)00596-2 doi: 10.1016/j.fertnstert.2014.07.001. [ Epub ahead of print]
   Google Scholar
• Woodcock J. Assessing the clinical utility of diagnostics used in drug therapy. Clin Pharmacol Ther 2010;88:765-73
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, O’Shanessy DJ, Albone E, et al. Co-development of diagnostics vectors to support targeted therapies and theranostics: essential tools in personalized cancer therapy. Front Oncol 2014;4:1-14
   PubMedGoogle Scholar
• Velagapudi SP, Gallo SM, Disney MD. Sequence-based design of bioactive small molecules that target precursor microRNAs. Nat Chem Biol 2014;10:291-7
   PubMed Web of Science ®Google Scholar
• Lundstrom K. Alphavirus-based vaccines. Viruses 2014;6:2392-415
   PubMed Web of Science ®Google Scholar
• Malone JG, Berglund PJ, Liljestrom P, et al. Mucosal immune responses associated with polynucleotide vaccination. Behring Inst Mitt 1997;98:63-72
   PubMedGoogle Scholar
• Schultz-Cherry S, Dybing JK, Davis NL, et al. Influenza virus (A/HK/156/97) hemagglutinin expressed by an alphavirus replicon system protects against lethal infection with Hong Kong-origin H5N1 viruses. Virology 2000;278:55-9
   PubMed Web of Science ®Google Scholar
• Bosworth B, Erdman MM, Stine DL, et al. Replicon particle vaccine protects swine against influenza. Comp Immunol Microbiol Infect Dis 2010;33:e99-e103
   PubMed Web of Science ®Google Scholar
• Brand D, Lemiale F, Turbica I, et al. Comparative analysis of humoral immune responses to HIV type 1 envelope glycoproteins in mice immunized with a DNA vaccine, recombinant Semliki Forest virus RNA, or recombinant Semliki Forest virus particles. AIDS Res Hum Retroviruses 1998;14:1369-77
   PubMed Web of Science ®Google Scholar
• Giraud A, Ataman-Onal Y, Battail N, et al. Generation of monoclonal antibodies to native human immunodeficiency virus type 1 envelope glycoprotein by immunization of mice with naked RNA. J Virol Methods 1999;79:75-84
   PubMedGoogle Scholar
• Caley IJ, Betts MR, Irlbeck DM, et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J Virol 1997;71:3031-8
   PubMed Web of Science ®Google Scholar
• Pushko P, Bray M, Ludwig GV, et al. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. Vaccine 2000;19:142-53
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hart MK. Protection from Ebola virus mediated by cytotoxic T-lymphocytes specific for the viral nucleoprotein. J Virol 2001;75:2660-4
   PubMed Web of Science ®Google Scholar
• Sheahan T, Whitmore A, Long K, et al. Successful vaccination strategies that protect aged mice from lethal challenge from influenza virus and heterologous severe acute respiratory syndrome coronavirus. J Virol 2011;85:217-30
   PubMed Web of Science ®Google Scholar
• Bhardwaj N, Heise MT, Ross TM. Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus. PLoS Negl Trop Dis 2010;4:e725
   Google Scholar
• Hooper JW, Ferro AM, Golden JW, et al. Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates. Vaccine 2009;28:494-511
   PubMed Web of Science ®Google Scholar
• Ip PP, Boerma A, Regts J, et al. Alphavirus-based vaccines encoding non-structural proteins of Hepatitis C virus induce robust and protective T cell responses. Mol Ther 2014;22(4):881-90
   PubMedGoogle Scholar
• Gaell AJ, Verma A, Otten GR, et al. Nonviral delivery of self-amplifying RNA vaccines. Proc Natl Acad Sci USA 2012;109:14604-9
   PubMedGoogle Scholar
• Andersson C, Vasconcelos NM, Sievertzon M, et al. Comparative immunization study using RNA and DNA constructs encoding a part of the Plasmodium falciparum antigen Pf332. Scand J Immunol 2001;54:117-24
   PubMedGoogle Scholar
• Thomas JM, Moen ST, Gnade BT, et al. Recombinant Sindbis virus vectors designed to express protective antigen of Bacillus anthracis protect animals from anthrax and display synergy with ciprofloxacin. Clin Vaccine Immunol 2009;16:1696-9
   PubMedGoogle Scholar
• Cabrera A, Sáez D, Céspedes S, et al. Vaccination with recombinant Semliki Forest virus particles expressing translation initiation factor 3 of Brucella abortus induces protective immunity in BALB/c mice. Immunobiology 2009;214:467-74
   PubMedGoogle Scholar
• Tsuji M, Bergmann CC, Takita-Sonoda Y, et al. Recombinant Sindbis viruses expressing a cytotoxic T-lymphocyte epitope of a malaria parasite or of influenza virus elicit protection against the corresponding pathogen in mice. J Virol 1998;72:6907-10
   PubMed Web of Science ®Google Scholar
• Krasemann S, Jürgens T, Bodemer W. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol 1999;73:119-29
   PubMedGoogle Scholar
• Avogadri F, Merghoub T, Maughan MF, et al. Alphavirus replicon particles expressing TRP-2 provide potent therapeutic effect on melanoma through activation of humoral and cellular immunity. PLoS One 2010;5:e12670
   PubMed Web of Science ®Google Scholar
• Colmenero P, Liljeström P, Jondal M. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Ther 1999;6:1728-33
   PubMed Web of Science ®Google Scholar
• Velders MP, McElhiney S, Cassetti MC, et al. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Cancer Res 2001;61:7861-7
   PubMed Web of Science ®Google Scholar
• Wang X, Wang JP, Rao XM, et al. Prime-boost vaccination with plasmid and adenovirus gene vaccines control HER2/neu+ metastatic breast cancer in mice. Breast Cancer Res 2005;7:R580-8
   Google Scholar
• Moran TP, Burgents JE, Long B, et al. Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice. Vaccine 2007;25:6604-12
   PubMed Web of Science ®Google Scholar
• Lyons JA, Sheahan BJ, Galbraith SE, et al. Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in mice. Gene Ther 2007;14:503-13
   PubMed Web of Science ®Google Scholar
• Cassetti MC, McElhiney SP, Shahabi V, et al. Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes. Vaccine 2004;22:520-7
   PubMed Web of Science ®Google Scholar
• Durso RJ, Andjelic S, Gardner JP, et al. A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin Cancer Res 2007;13:3999-4008
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez ML, Gray A, Hubby B, et al. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Cancer Res 2007;67:1344-51
   PubMedGoogle Scholar
• Garcia-Hernandez ML, Gray A, Hubby B, et al. Prostate stem cell antigen vaccination induces a long-term protective immune response against prostate cancer in the absence of autoimmunity. Cancer Res 2008;68:861-9
   PubMed Web of Science ®Google Scholar
• Yamanaka R, Zullo SA, Ramsey J, et al. Induction of therapeutic antitumor antiangiogenesis by intratumoral injection of genetically engineered endostatin-producing Semliki Forest virus. Cancer Gene Ther 2001;8:796-802
   PubMedGoogle Scholar
• Yamanaka R, Xanthopoulos KG. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of Sindbis DNA encoding gp100 and IL-18. DNA Cell Biol 2005;24:317-24
   PubMed Web of Science ®Google Scholar
• Van Lint S, Thielemans K, Breckpot K. mRNA: delivering an antitumor message? Immunotherapy 2011;3:605-7
   PubMedGoogle Scholar
• Fotin-Mleczek M, Duchardt KM, Lorenz C, et al. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J Immunother 2011;34:1-15
   PubMed Web of Science ®Google Scholar
• Kreiter S, Diken M, Selmi A, et al. FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines. Cancer Res 2011;71:6132-42
   PubMed Web of Science ®Google Scholar
• Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72:1661-71
   PubMed Web of Science ®Google Scholar
• Van Lint S, Wilgenhof S, Heirman C, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother 2014;63(9):959-67
   PubMed Web of Science ®Google Scholar
• Chua AJ, Vituret C, Tan ML, et al. A novel platform for virus-like particle-display of flaviviral envelope domain III: induction of Dengue and West Nile virus neutralizing antibodies. Virol J 2013;10:129
   PubMed Web of Science ®Google Scholar
• Bennett AM, Elvin SJ, Wright AJ, et al. An immunological profile of Balb/c mice protected from airborne challenge following vaccination with a live attenuated Venezuelan equine encephalitis virus vaccine. Vaccine 2000;19:337-47
   PubMed Web of Science ®Google Scholar
• Hart MK, Caswell-Stephan K, Bakken R, et al. Improved mucosal protection against Venezuelan equine encephalitis virus is induced by the molecularly defined, live-attenuated V3526 vaccine candidate. Vaccine 2000;18:3067-75
   PubMed Web of Science ®Google Scholar
• Schoepp RJ, Smith JF, Parker MD. Recombinant chimeric western and eastern equine encephalitis viruses as potential vaccine candidates. Virology 2002;302:299-309
   PubMed Web of Science ®Google Scholar
• Kim DY, Atasheva S, Foy NJ, et al. Design of chimeric alphaviruses with a programmed, attenuated, cell type-restricted phenotype. J Virol 2011;85:4363-76
   PubMed Web of Science ®Google Scholar
• Dash PK, Tiwari M, Santhosh SR, et al. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 2008;376:718-22
   PubMed Web of Science ®Google Scholar
• Kamrud KI, Coffield VM, Owens G, et al. In vitro and in vivo characterization of microRNA-targeted alphavirus replicon and helper RNAs. J Virol 2010;84:7713-25
   PubMed Web of Science ®Google Scholar
• Bhomia M, Sharma A, Gayen M, et al. Artificial microRNAs can effectively inhibit replication of Venezuelan equine encephalitis virus. Antivir Res 2013;100:429-34
   PubMed Web of Science ®Google Scholar
• Edelman R, Tacket CO, Wasserman SS, et al. Phase II safety and immunogenicity study of live Chikungunya virus vaccine TSI-GSD-218. Am J Trop Med Hyg 2000;62:681-5
   PubMed Web of Science ®Google Scholar
• Bernstein DI, Reap EA, Katen K, et al. Randomized, double-blind, Phase 1 trial of an alphavirus replicon vaccine for cytomegalovirus in CMV seronegative adult volunteers. Vaccine 2009;28:484-93
   PubMed Web of Science ®Google Scholar
• Morse MA, Hobeika AC, Osada T, et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J Clin Invest 2010;120:3234-41
   PubMed Web of Science ®Google Scholar
• Slovin SF, Kehoe M, Durso R, et al. A phase I dose escalation trial of vaccine replicon particles (VRP) expressing prostate-specific membrane antigen (PSMA) in subjects with prostate cancer. Vaccine 2013;31:943-9
   PubMed Web of Science ®Google Scholar
• Mallilankaraman K, Shedlock DJ, Bao H, et al. A DNA vaccine against Chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011;5:e928
   PubMed Web of Science ®Google Scholar
• Kramer RM, Zeng Y, Sahni N, et al. Development of a stable virus-like particle vaccine formulation against Chikungunya virus and investigation of the effects of polyanions. J Pharm Sci 2013;102:4305-14
   PubMed Web of Science ®Google Scholar